Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical Outlook
  • Published:

Metabolic alliance: pharmacotherapy and exercise management of obesity

Nature Reviews Endocrinology (2024)Cite this article

Subjects

Anti-obesity medications based on incretin hormones have advanced weight control and metabolic health in individuals with obesity. The long-term success of obesity therapeutics could be facilitated by exercise, a vital metabolic ally in enhancing treatment efficacy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Benefits of pharmacotherapy and exercise on obesity and human metabolism.

References

  1. Jensen, S. B. K. et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. EClinicalMedicine 69, 102475 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Ansari, S., Khoo, B. & Tan, T. Targeting the incretin system in obesity and type 2 diabetes mellitus. Nat. Rev. Endocrinol. https://doi.org/10.1038/s41574-024-00979-9 (2024).

    Article  PubMed  Google Scholar 

  3. Jastreboff, A. M. et al. Triple–hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New Eng. J. Med. 389, 514–526 (2023).

    Article  CAS  PubMed  Google Scholar 

  4. Jensen, S. B. K. et al. Weight loss maintenance with exercise and liraglutide improves glucose tolerance, glucagon response, and beta cell function. Obesity 31, 977–989 (2023).

    Article  CAS  PubMed  Google Scholar 

  5. Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New Eng. J. of Med. 389, 2221–2232 (2023).

    Article  CAS  Google Scholar 

  6. García-Vega, D. et al. Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network. Cardiovasc. Diabetol. 23, 1 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Ashcroft, S. P., Stocks, B., Egan, B. & Zierath, J. R. Exercise induces tissue-specific adaptations to enhance cardiometabolic health. Cell Metab. 36, 278–300 (2024).

    Article  CAS  PubMed  Google Scholar 

  8. Corbin, K. D. et al. Glucagon-like peptide-1/glucagon receptor agonism associates with reduced metabolic adaptation and higher fat oxidation: A randomized trial. Obesity 31, 350–362 (2023).

    Article  CAS  PubMed  Google Scholar 

  9. Melson, E., Ashraf, U., Papamargaritis, D. & Davies, M. J. What is the pipeline for future medications for obesity? Int. J. Obes. https://doi.org/10.1038/s41366-024-01473-y (2024).

    Article  Google Scholar 

  10. Herrou, J. et al. Narrative review of effects of glucagon-like peptide-1 receptor agonists on bone health in people living with obesity. Calcif. Tissue Int. 114, 86–97 (2024).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. LFE Research Group, Department of Health and Human Performance, Faculty of Physical Activity and Sport Sciences (INEF), Universidad Politécnica de Madrid (UPM), Madrid, Spain

    Javier Butragueño

  2. Department of Physical Education and Sports, Faculty of Sport Sciences, Sport and Health University Research Institute (iMUDS), University of Granada, Granada, Spain

    Jonatan R. Ruiz

  3. Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III, Madrid, Spain

    Jonatan R. Ruiz

  4. Instituto de Investigación Biosanitaria, Ibs.Granada, Granada, Spain

    Jonatan R. Ruiz

Authors
  1. Javier Butragueño
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonatan R. Ruiz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Javier Butragueño or Jonatan R. Ruiz.

Ethics declarations

Competing interests

Javier Butragueño has served as a speaker for exercise training sessions for Novo Nordisk Inc. and Eli Lilly Inc. Jonatan R. Ruiz declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Butragueño, J., Ruiz, J.R. Metabolic alliance: pharmacotherapy and exercise management of obesity. Nat Rev Endocrinol (2024). https://doi.org/10.1038/s41574-024-01006-7

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41574-024-01006-7

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing